MacLellan Jeffrey D, Arnold Susan A, Dave Aditya C, Hunt Matthew A, Pluhar G Elizabeth
J Am Vet Med Assoc. 2018 Jan 1;252(1):98-102. doi: 10.2460/javma.252.1.98.
OBJECTIVE To assess the relationship between preoperative volume of primary intracranial gliomas in dogs as determined via MRI and survival time after surgical debulking and adjunctive immunotherapy. DESIGN Retrospective cohort study. ANIMALS 47 client-owned dogs enrolled in clinical trials regarding glioma treatments. PROCEDURES Medical records of all dogs undergoing craniotomy at the University of Minnesota Veterinary Medicine Center with histologically confirmed glioma between 2008 and 2015 were retrospectively reviewed, and outcome data were collected. Preoperative T2-weighted or post-gadolinium administration T1-weighted MRI scans, performed at several referral institutions with scanners of magnet strengths ranging from 0.5 to 3.0 T, were used to measure tumor volumes as a percentage of total calvarial volume. Data were analyzed to assess the effect of each 2% fraction of tumor volume on median survival time (MST) after surgery and adjuvant treatment. RESULTS Tumor volumes ranged from 0.5% to 12.2% of total intracranial volume. Overall MST was 185 days (range, 2 to 802 days). No association was identified between preoperative tumor volume and MST. Only 3 (6%) dogs had low-grade tumors that had relatively small volumes, measuring 1.4%, 2.1%, and 4.3% of total calvarial volume. The MST for these 3 dogs (727 days) was longer than that for high-grade tumors (174 days); however, owing to the low number of dogs with low-grade tumors, no statistical comparison was performed. CONCLUSIONS AND CLINICAL RELEVANCE Preoperative tumor volume determined via MRI was neither associated with nor predictive of outcome following surgery and adjunctive treatment for dogs with glioma. Tumor grade was predictive of outcome, but unlike tumor volume that was measured with MRI, invasive biopsy was necessary to definitively diagnose tumor grade.
目的 评估通过MRI测定的犬原发性颅内胶质瘤术前体积与手术减压及辅助免疫治疗后的生存时间之间的关系。 设计 回顾性队列研究。 动物 47只参加胶质瘤治疗临床试验的客户拥有的犬。 程序 回顾性审查了2008年至2015年在明尼苏达大学兽医学院接受开颅手术且组织学确诊为胶质瘤的所有犬的病历,并收集了结局数据。在几个转诊机构使用磁场强度范围为0.5至3.0 T的扫描仪进行的术前T2加权或钆增强后T1加权MRI扫描,用于测量肿瘤体积占总颅骨体积的百分比。分析数据以评估肿瘤体积每增加2%对手术和辅助治疗后中位生存时间(MST)的影响。 结果 肿瘤体积占颅内总体积的0.5%至12.2%。总体MST为185天(范围为2至802天)。术前肿瘤体积与MST之间未发现关联。只有3只(6%)犬患有低级别肿瘤,体积相对较小,分别占总颅骨体积的1.4%、2.1%和4.3%。这3只犬的MST(727天)长于高级别肿瘤犬(174天);然而,由于低级别肿瘤犬数量较少,未进行统计学比较。 结论及临床意义 通过MRI测定的术前肿瘤体积与犬胶质瘤手术及辅助治疗后的结局既无关联也不能预测。肿瘤级别可预测结局,但与通过MRI测量的肿瘤体积不同,明确诊断肿瘤级别需要进行侵入性活检。